Long-term Outcomes of Augmentation Enterocystoplasty in Patients With End-Stage Bladder Diseases: A Single-Institute Experience Involving 102 Patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Augmentation enterocystoplasty (AE) has been shown to improve clinical symptoms in patients with end-stage bladder disease (ESBD). Herein, we report the long-term outcomes of a series of patients with different etiologies of ESBD who received AE. Methods: We retrospectively reviewed 102 patients with ESBD who received AE at the Hualien Tzu Chi General Hospital from 1992 to 2014. ESBD in this study was defined as including neurogenic lower urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI) or myelomeningocele, inflammatory bladder disease (IBD), ESBD occurring after pelvic cancer surgery, and other etiologies. Complications including active lower urinary tract problems and urinary tract infection (UTI), as well as patients’ self-reported satisfaction with the procedure, were evaluated. Results: A total of 102 patients were included in the study. A majority of patients received AE for NLUTD (n=43), followed by IBD (n=38), ESBD after pelvic cancer surgery (n=15), and the other etiologies (n=6). Patients had a mean age of 39.4±18.7 years and were followed for a mean of 78 months. All patients had significantly increased cystometric bladder capacity and compliance at the time of follow-up. Fifty-four patients (52.9%) reported moderate to excellent satisfaction with the outcome, and there were no significant differences among the groups (P=0.430). The most common reason for dissatisfaction was the need for clean intermittent catheterization (CIC; 41.7%), followed by urinary incontinence (25.0%) and recurrent UTI (16.7%). Conclusions: AE is a safe and effective procedure for patients with ESBD. Postoperative urinary incontinence and UTI as well as the need for CIC may affect quality of life and decrease patient satisfaction.
Abstract
Purpose: Augmentation enterocystoplasty (AE) has been shown to improve clinical symptoms in patients with end-stage bladder disease (ESBD). Herein, we report the long-term outcomes of a series of patients with different etiologies of ESBD who received AE. Methods: We retrospectively reviewed 102 patients with ESBD who received AE at the Hualien Tzu Chi General Hospital from 1992 to 2014. ESBD in this study was defined as including neurogenic lower urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI) or myelomeningocele, inflammatory bladder disease (IBD), ESBD occurring after pelvic cancer surgery, and other etiologies. Complications including active lower urinary tract problems and urinary tract infection (UTI), as well as patients’ self-reported satisfaction with the procedure, were evaluated. Results: A total of 102 patients were included in the study. A majority of patients received AE for NLUTD (n=43), followed by IBD (n=38), ESBD after pelvic cancer surgery (n=15), and the other etiologies (n=6). Patients had a mean age of 39.4±18.7 years and were followed for a mean of 78 months. All patients had significantly increased cystometric bladder capacity and compliance at the time of follow-up. Fifty-four patients (52.9%) reported moderate to excellent satisfaction with the outcome, and there were no significant differences among the groups (P=0.430). The most common reason for dissatisfaction was the need for clean intermittent catheterization (CIC; 41.7%), followed by urinary incontinence (25.0%) and recurrent UTI (16.7%). Conclusions: AE is a safe and effective procedure for patients with ESBD. Postoperative urinary incontinence and UTI as well as the need for CIC may affect quality of life and decrease patient satisfaction.
참고문헌 (17)
- Blaivas JG, "Longterm followup of augmentation enterocystoplasty and continent diversion in patients with benign disease", J Urol, 173, pp.1631~1634 (2005)
- Oelke M, "Increase in detrusor wall thickness indicates bladder outlet obstruction(BOO)in men", World J Urol, 19, pp.443~452 (2002)
- Chu PS, "The destruction of the lower urinary tract by ketamine abuse: a new syndrome?", BJU Int, 102, pp.1616~1622 (2008)
- Chen JL, "Long-term outcomes of augmentation enterocystoplasty with an ileal segment in patients with spinal cord injury", J Formos Med Assoc, 108, pp.475~480 (2009)
- Mitrofanoff P, "Trans-appendicular continent cystostomy in the management of the neurogenic bladder", Chir Pediatr, 21, pp.297~305 (1980)
- Lendvay TS, "Augmentation cystoplasty rates at children’s hospitals in the United States: a pediatric health information system database study", J Urol, 176(4 Pt 2), pp.1716~1720 (2006)
- Edelstein RA, "The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy", J Urol, 154, pp.1500~1504 (1995)
- Reyblat P, "Augmentation cystoplasty: what are the indications?", Curr Urol Rep, 9, pp.452~458 (2008)
- Ku JH, "The management of neurogenic bladder and quality of life in spinal cord injury", BJU Int, 98, pp.739~745 (2006)
- Hautmann RE, "The ileal neobladder", J Urol, 139, pp.39~42 (1988)
- Propert KJ, "Responsiveness of symptom scales for interstitial cystitis", Urology, 67, pp.55~59 (2006)
- Scales CD Jr, "Evaluating outcomes of enterocystoplasty in patients with spina bifida : a review of the literature", J Urol, 180, pp.2323~2329 (2008)
- Welk B, "Population based assessment of enterocystoplasty complications in adults", J Urol, 188, pp.464~469 (2012)
- Hendren WH, "Bladder augmentation: experience with 129 children and young adults", J Urol, 144(2 Pt 2), pp.445~453 (1990)
- Kuo HC, "Clinical outcome and quality of life after enterocystoplasty for contracted bladders", Urol Int, 58, pp.160~165 (1997)
- Herschorn S, "Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder", Urology, 52, pp.672~678 (1998)
- Shekarriz B, "Surgical complications of bladder augmentation : comparison between various enterocystoplasties in 133 patients", Urology, 55, pp.123~128 (2000)